NCT01344564View on ClinicalTrials.gov

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

NACompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Prostate Cancer

Interventions

DRUG

Degarelix acetate, Leuprolide acetate

Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once

Trial Locations (1)

23462

Urology of Virginia, Virginia Beach

Sponsors

Collaborators (1)

Ferring Pharmaceuticals

All Listed Sponsors

collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Urology of Virginia

OTHER

NCT01344564 - Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide | Biotech Hunter | Biotech Hunter